You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
|
|---|---|
| Published in |
Oncotarget, October 2015
|
| DOI | 10.18632/oncotarget.6056 |
| Pubmed ID | |
| Authors |
Hyo Song Kim, Sung-Moo Kim, Hyunki Kim, Kyoung-Ho Pyo, Jong-Mu Sun, Myung-Ju Ahn, Keunchil Park, Bhumsuk Keam, Nak-Jung Kwon, Hwan Jung Yun, Hoon-Gu Kim, Ik-Joo Chung, Jong Seok Lee, Kyung Hee Lee, Dae Joon Kim, Chang-Geol Lee, Jin Hur, Hyunsoo Chung, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, Hye Ryun Kim, Yong Wha Moon, Yong Chan Lee, Joo Hang Kim, Soonmyung Paik, Byoung Chul Cho |
| Abstract |
The purpose of this study was to investigate the clinical activity, safety and predictive biomarkers of dacomitinib, an irreversible pan-HER inhibitor, in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC). Patients, whose diseases were not amenable to curative treatment and had progressed on platinum-based chemotherapy, were treated with dacomitinib 45mg/day. The primary endpoint was objective response rate by RECISTv 1.1. Predictive biomarker analyses included the characterization of somatic mutations and gene expression using the Ion Torrent AmpliSeq Cancer Hotspot Panel and Nanostring nCounter, and investigation of their relationship with clinical outcomes. Of the 48 evaluable patients, 6 (12.5%) achieved partial responses and 29 (60.4%) had stable disease. The median response duration was 7.1 months. The median progression free survival (PFS) and overall survival (OS) was 3.3 months (95% CI, 2.4-4.3 months) and 6.4 months (95% CI, 4.4-8.4 months). Adverse events were mostly grade 1-2. Gene set enrichment analysis revealed that ERBB signaling pathway is significantly enriched in patients with PFS ≥4 months (n = 12) than PFS < 4 months (n = 21) (p < 0.001). Upregulation of ERBB signaling pathway was significantly associated with longer PFS (5.0 vs. 2.9 months, P = 0.016) and OS (10.0 vs. 4.8 months, P = 0.022). The most frequent mutations were TP53 (61%) followed by CDKN2A (8%), MLH1 (8%), FLT3 (8%) and EGFR (8%). Dacomitinib demonstrated clinical efficacy with manageable toxicity in platinum-failed R/M-ESCC. Screening of ERBB pathway-related gene expression profiles may help identify patients who are most likely benefit from dacomitinib. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 52 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 15% |
| Student > Master | 7 | 13% |
| Student > Ph. D. Student | 7 | 13% |
| Student > Bachelor | 5 | 10% |
| Professor | 3 | 6% |
| Other | 4 | 8% |
| Unknown | 18 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 35% |
| Biochemistry, Genetics and Molecular Biology | 6 | 12% |
| Agricultural and Biological Sciences | 3 | 6% |
| Psychology | 2 | 4% |
| Economics, Econometrics and Finance | 2 | 4% |
| Other | 4 | 8% |
| Unknown | 17 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2023.
All research outputs
#6,969,786
of 23,305,591 outputs
Outputs from Oncotarget
#3,032
of 14,405 outputs
Outputs of similar age
#84,144
of 279,841 outputs
Outputs of similar age from Oncotarget
#151
of 806 outputs
Altmetric has tracked 23,305,591 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 14,405 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,841 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 806 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.